Eli Lilly to take over development of diabetes treatment

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Indy-based drugmaker Eli Lilly is taking over the development of a potential diabetes treatment.

Lilly is paying Canadian company Transition Therapeutics $7 million to take over the project.

The drug is heading into mid-stage clinical testing. It’s being developed to treat type-2 diabetes, which is the most common form of the illness.

Transition could receive millions in royalties if the drug is eventually approved and sold.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.